ROGER CHAMMAS

(Fonte: Lattes)
Índice h a partir de 2011
27
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Radiologia, Faculdade de Medicina - Docente
LIM/05 - Laboratório de Poluição Atmosférica Experimental, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Mostrar mais
Limpar filtros

Configurações

Categoria: meeting abstract ×

Resultados de Busca

Agora exibindo 1 - 10 de 40
  • conferenceObject
    Melatonin treatment: A transcriptomic networks in a xenograft model of breast cancer
    (2017) JARDIM-PERASSI, B. V.; SONEHARA, N. M.; PAULA-JUNIOR, R. de; CHAMMAS, R.; COUTINHO, L. L.; REIS JUNIOR, O.; ALEXANDRE, P. A.; FUKUMASU, H.; ZUCCARI, D. A. P. C.
  • conferenceObject
    Correlation of a microRNA expression profile and the prognosis of penile cancer: A prospective study using microarray data analysis
    (2018) FURUYA, Tatiane K.; MURTA, Claudio B.; PONTES JR., Jose; UNO, Miyuki; CARRASCO, Alexis; SICHERO, Laura C.; VILLA, Luisa L.; COELHO, Rafael F.; GUGLIELMETTI, Giuliano B.; CORDEIRO, Mauricio D.; LEITE, Katia R.; SROUGI, Miguel; CHAMMAS, Roger; NAHAS, William C.
  • conferenceObject
    Stochastic model of contact inhibition and the proliferation of melanoma in situ.
    (2018) MORAIS, Mauro Cesar C.; STUHL, Izabella; SABINO, Alan U.; LAUTENSCHLAGER, Willian W.; QUEIROGA, Alexandre S.; TORTELLI JR., Tharcisio C.; CHAMMAS, Roger; SUHOV, Yuri; RAMOS, Alexandre F.
  • conferenceObject
    Comparative evaluation of a trastuzumab biosimilar or originator trastuzumab in association with pertuzumab: Binding and biological activities in cell culture-based assays
    (2020) PIMENTEL, Franklin F.; TOLEDO, Juliano S.; GONCALVES, Joao; ALVES, Leandro L.; PAULA, Mayara I. de; ANDRADE, Jurandyr M. de; TIEZZI, Daniel G.; CHAMMAS, Roger
  • conferenceObject
    Synthesis and Preliminary Assessment of (99)m tc-HYNICF-ab's (Rituximab) for Non-Hodgkin Lymphoma Diagnosis
    (2014) CAMACHO, Ximena; MACHADO, Camila; BANCHERO, Agustina; GARCIA, Maria Fernanda; CALZADA, Victoria; FERNANDEZ, Marcelo; MORENO, Maria; GAMBINI, Juan Pablo; ALONSO, Omar; CHAMMAS, Roger; CABRAL, Pablo; RIVA, Eloisa
  • conferenceObject
    ERCC1 AND BETA-TUBULIN III IN ADVANCED NSCLC PATIENTS TREATED WITH CISPLATIN-VINORELBINE
    (2012) CASTRO JR., G. de; VICTOR, C. R.; BIGATON, F. J.; TAKAHASHI, T. K.; FEHER, O.; SABER, A. M. Ab'; TAKAGAKI, T. Y.; SIQUEIRA, S. A. C.; CHAMMAS, R.; HOFF, P. M. G.
    Background: Platinum-containing chemotherapy remains as the standard treatment in advanced/metastatic non-small-cell lung cancer (NSC LC) patients (pts). Increased ERCC 1 expression has been associated with resistance to platinum-based therapies, and beta-tubulin III (TUBB 3) was shown to be involved in resistance to antimicrotubule agents. Here we studied these tumor markers in NSC LC pts treated with cisplatin-vinorelbine and correlated their expression with survival. Methods: It is a retrospective study on pts diagnosed with advanced/metastatic NSC LC (TNM 6th ed), consecutively identified. All pts were treated with cisplatin 80 mg/m2 d1 and vinorelbine 30 mg/m2 d1, d8, d15, every 21 days, 4–6 cycles, in our Institution, between Sep/2002 and Oct/2008. ERCC 1 (clone 8F1) and TUBB 3 (clone TUJ1) expression were evaluated by immunohistochemistry, and biomarker expression was considered as high when more than 10% of tumor cells presented moderate to strong staining, nuclear or cytoplasmic, respectively. Overall survival (OS) was estimated by the Kaplan-Meier method and curves were compared with log-rank. Results: 142 pts were studied; median age 63 y (34-87), 67% male and 86% current smokers. Adenocarcinoma (ADC, 58 pts, 43%), followed by squamous cell carcinoma (SCC , 50 pts, 37%) were the most frequent histologic types. 100 pts (71%) were staged as IV and 34 pts (24%) as IIIB. The median number of cycles was 4 (1-7). Median OS was 7.9 mo. Overall, high ERCC 1 expression was observed in 61/104 pts (59%) and high TUBB 3 expression in 55/109 pts (51%). According to histologic types, low ERCC 1 expression was observed in 7/42 SCC pts (16%) and in 35/63 ADC pts (56%) (p=0.0004). Among ADC pts, 1-y OS rate was 28% and 47% in pts which tumors presented with high and low ERCC 1 expression, respectively (HR 1.57, 95% CI 0.9-2.7, p=0.08). TUBB 3 expression neither presented any difference between SCC and ADC types, nor any prognostic impact in terms of OS. Conclusions: Low ERCC 1 expression was observed more frequently in pts with advanced lung ADC and it was a favorable prognostic factor in ADC pts treated with cisplatin-vinorelbine.
  • conferenceObject
    Near Infrared Fluorescence In-Vivo Imaging of Non-Hodgkin Lymphoma Using Cy7-Bevacizumab
    (2017) CAMACHO, Ximena; PERRONI, Carolina; JUNQUEIRA, Mara de Souza; FERNANDEZ, Marcelo; BUSTOS, Silvina; BUCHPIGUEL, Carlos; CHAMMAS, Roger; GAMBINI, Juan Pablo; CABRAL, Pablo; RIVA, Eloisa
  • conferenceObject
    Eeyarestatin I sensitizes melanoma cells to cisplatin-induced cell death
    (2018) SAITO, Renata de Freitas; OTAKE, Andreia Hanada; CORTEZ, Margarita M.; GILLIES, Robbert J.; CHAMMAS, Roger
  • conferenceObject
    7-Ketocholesterol loaded-phosphatidylserine liposome induces cell death, autophagy, and growth inhibition of melanoma and breast adenocarcinoma.
    (2018) FAVERO, Giovani Marino; TORTELLI JR., Tharcisio Citrangulo; FERNANDES, Daniel; PRESTES, Ana Paula; KMETIUK, Louise N. B.; OTAKE, Andreia Hanada; ANDRADE, Luciana N. S.; FARIA, Daniele de Paula; CARNEIRO, Camila de Godoi; GARCEZ, Alexandre Teles; MARQUES, Fabio L. N.; CHAMMAS, Roger
  • conferenceObject
    MicroRNA-195 acts as a tumor suppressor miRNA in human melanoma cells by targeting Prohibitin 1.
    (2018) CIRILO, Priscila D. R.; CORREA, Bruna R. S.; QIAO, Mei; ANDRADE, Luciana N. S.; CHAMMAS, Roger; PENALVA, Luiz O. F.